Phathom Pharmaceuticals, Inc. PHAT
5.45 USD +0.12 (+2.16%)
At closeNov 10, 2026, 6:01 PM EST
5.73 +0.29 +5.23%
After hours · Nov 10, 6:01 PM ET
5.15 Day range 5.55
5.02 52-week range 18.31
- YTD
- -67.18%
- 1 year
- -60.34%
News
zacks.com Implied Volatility Surging for Phathom Pharmaceuticals Stock Options Investors need to pay close attention to PHAT stock based on the movements in the options market lately.
globenewswire.com Phathom Pharmaceuticals to Participate in November Investor Conferences FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for…
benzinga.com Phathom Pharmaceuticals Announces $0 Payment From Eligible Commercially Insured Patients For VOQUEZNA Tablets Through BlinkRx Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal diseases, today announced that eligible…
globenewswire.com Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx A Media Snippet accompanying this announcement is available by clicking on this link.
marketbeat.com What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call Phathom Pharmaceuticals NASDAQ: PHAT reported third-quarter 2026 revenue growth and a second consecutive quarter of positive operating profit excluding stock-based compensation, as the company…
seekingalpha.com Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call Transcript Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call Transcript
zacks.com Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates Phathom Pharmaceuticals, Inc. (PHAT) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.15 per share a year…
benzinga.com Phathom Pharmaceuticals Q3 2026 Earnings Call Transcript Phathom Pharmaceuticals (NASDAQ:PHAT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $310.000M-$325.000M vs $314.842M Est Phathom Pharmaceuticals (NASDAQ:PHAT) affirms FY2026 sales outlook from $310.000 million-$325.000 million to $310.000 million-$325.000 million vs $314.842 million estimate.
benzinga.com Phathom Pharmaceuticals Q3 Adj. EPS $0.04 Beats $0.02 Estimate, Sales $84.722M Miss $85.096M Estimate Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.02 by 100 percent. This is a 126.67 percent increase over losses…
globenewswire.com Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update Over 2 million total VOQUEZNA® prescriptions filled through October 16, 2026 Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs.
globenewswire.com Phathom Pharmaceuticals Provides Update on FDA Litigation FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for…
globenewswire.com Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA FLORHAM PARK, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for…
globenewswire.com Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026 Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDT Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDT- benzinga.com Phathom Pharmaceuticals To Present New Cost-Effectiveness Data For VOQUEZNA At The American College Of Gastroenterology Meeting, October 9-14; New analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for adults with Erosive GERD, with potential cost savings at…
globenewswire.com Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting Three scientific presentations will highlight new analyses of VOQUEZNA® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in…
benzinga.com Phathom Pharmaceuticals Initiates Registrational Phase 3 Study Of VOQUEZNA For As-Needed Treatment Of Non-Erosive GERD Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results…
globenewswire.com Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results…
defenseworld.net Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month Low – Time to Sell? Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report)'s stock price hit a new 52-week low during trading on Thursday. The stock traded as low as $7.66 and last traded at $7.69, with a volume…
gurufocus.com PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law [url="]Schall, Brown and Schwartz LLP[/url] (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
businesswire.com PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $PHAT--PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
benzinga.com Leerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10 Leerink Partners analyst Daniel Clark initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Market Perform rating and announces Price Target of $10.
globenewswire.com Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for…
benzinga.com Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14 Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $18 to $14.
globenewswire.com Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT) Phathom Pharmaceuticals' revised FY 2026 revenue outlook of $310 million -- $325 million came in below the roughly $332 million -- $334 million analysts were modeling, and PHAT shares sold off on the…
businesswire.com PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT) NEW YORK--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) shareholders took losses after the Company lowered its full-year 2026 revenue guidance to $310 million–$325 million from its…- benzinga.com Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22 Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $22.
prnewswire.com PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals /PRNewswire/ -- Investors in Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) were told the Company's full-year revenue guidance was intact -- then watched that
benzinga.com HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.
seekingalpha.com Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript- benzinga.com Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22 Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $28 to $22.
- benzinga.com Phathom Pharmaceuticals Q2 Adj. EPS $0.00 Beats $(0.25) Estimate, Sales $74.300M Beat $72.789M Estimate Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.25) by 100 percent. This is a 100 percent increase over losses of…
- benzinga.com Phathom Pharmaceuticals Lowers FY2026 Sales Guidance from $320.000M-$345.000M to $310.000M-$325.000M vs $332.196M Est Phathom Pharmaceuticals (NASDAQ:PHAT) lowers FY2026 sales outlook from $320.000 million-$345.000 million to $310.000 million-$325.000 million vs $332.196 million estimate.
benzinga.com Phathom Pharmaceuticals Q2 Sales $74.300M Beat $72.789M Estimate Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly sales of $74.300 million which beat the analyst consensus estimate of $72.789 million by 2.08 percent. This is a 88.09 percent increase over…
benzinga.com Phathom Pharmaceuticals Completes Patient Enrollment In Its Phase 2 pHalcon-EoE-201 Clinical Study Of VOQUEZNA Tablets To Treat Eosinophilic Esophagitis In Adults Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced it has…- benzinga.com HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.
benzinga.com Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript 
benzinga.com Earnings Scheduled For April 30, 2026 - benzinga.com Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $320.000M-$345.000M vs $331.417M Est Phathom Pharmaceuticals (NASDAQ:PHAT) affirms FY2026 sales outlook from $320.000 million-$345.000 million to $320.000 million-$345.000 million vs $331.417 million estimate.
- benzinga.com Phathom Pharmaceuticals Q1 Adj. EPS $(0.18) Beats $(0.32) Estimate, Sales $58.301M Beat $57.028M Estimate Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.32) by 43.75 percent. This is a 83.18 percent increase over…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com This Argan Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday Top Wall Street analysts upgraded PHAT and PWR, while AGX was upgraded to Overweight with a $550 price target. Check out analysts' views on these stocks.- benzinga.com Barclays Upgrades Phathom Pharmaceuticals to Overweight, Raises Price Target to $18 Barclays analyst Glen Santangelo upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) from Equal-Weight to Overweight and raises the price target from $16 to $18.
- benzinga.com Guggenheim Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $25 Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and raises the price target from $20 to $25.
- benzinga.com Phathom Pharmaceuticals Sees FY2026 Sales $320.000M-$345.000M vs $314.481M Est Phathom Pharmaceuticals (NASDAQ:PHAT) sees FY2026 sales of $320.000 million-$345.000 million vs $314.481 million analyst estimate.
benzinga.com Phathom Pharmaceuticals Earnings Review: Q4 Summary - benzinga.com Phathom Pharmaceuticals Q4 Adj. EPS $(0.08) Beats $(0.38) Estimate, Sales $57.584M Beat $57.050M Estimate Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.38) by 79 percent. This is a 89.87 percent increase over losses…
- benzinga.com Earnings Scheduled For February 26, 2026
benzinga.com Phathom Pharma Shows Sales Strength, Targets 2026 Profitability Phathom Pharmaceuticals (NASDAQ: PHAT) reported Q4 sales of $57-$58 million, updated FY2025 revenue guidance to $174.5-$175.5 million.
benzinga.com Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) (Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the story.) U.S. stock futures declined on Thursday following a mixed close on Tuesday, with only the…